Are You Cowmaxxing?
Beef tallow (as both a moisturizer and an alternative to seed oils) is one of many cow-based products that have crowded the wellness market in the past five or so years. Beef-bone broth is a grocery-store staple. Demand for raw milk has grown, despite numerous cases of illness and warnings from public-health officials that drinking it can be fatal. In certain circles, raw cow organs—heart, liver, kidney—are prized superfoods. Target and Walmart sell supplements containing bovine collagen (a protein found in cowhide and bone) and colostrum (the rich liquid that mammals produce for their newborn offspring); they promise healthier skin, a happier gut, and stronger immunity, and come in flavors such as watermelon lime, lemon sorbet, and 'valiant grape.' You can buy cow-placenta pills for postpartum healing, or powdered bull testicle for testosterone support. The slightest interaction with clean-beauty Instagram can fill your feed with ads for beef-tallow lip balms, cleansing creams, sunscreen, and deodorants. (One brand even offers creamsicle-flavored beef-tallow personal lubricant, which is currently out of stock online.) Influencers praise tallow for clearing their acne and eczema—and offer discount codes so you can experience the same.
Even the government's recent public-health messaging has veered toward the bovine. During his tenure as health secretary, Robert F. Kennedy Jr. has championed cooking in beef tallow (which he says is healthier than seed oils) and drinking raw milk (one of many items that he claims are suppressed by the FDA). Casey Means, President Donald Trump's nominee for surgeon general, also supports raw milk; she has suggested that Americans can decide whether a given bottle is safe to drink by looking the dairy farmer in the eye and petting his cow. Means and Kennedy have largely avoided engaging with the many public-health experts who reject their views. But in May, after months of such critiques, Kennedy took shots of raw milk at the White House to celebrate the release of the 'Make America Healthy Again' report.
Woo-woo, it seems, is becoming moo-moo. America has entered its cowmaxxing era.
Like most wellness offerings, cow products are marketed with vague health claims that are virtually impossible to confirm or deny, such as 'deeply nourishes and supports the skin barrier,' 'activate cellular health,' and 'supports memory.' One of the many promises of the Ancestral Supplements Starter Pack of organ-based capsules is simply 'vitality.' (The company also includes a disclaimer that the FDA has not reviewed said vitality benefits.) Advocates of these goods tend to be more specific in their praise. Raw-milk enthusiasts claim that unpasteurized milk contains bioactive chemicals that improve human health. In one video, a woman drinks raw milk that's been in the fridge for more than a month; she claims it is safer to consume than store-bought pizza or salad and that it reduces rates of eczema, fevers, and respiratory infections. One smooth-skinned influencer, who says she hasn't washed her face in two years, claims that beef tallow is 'bioidentical' to the sebum produced by human skin. (It's not, because it's from cows.)
Some of these products are more likely to provide benefits than others. Bone broth is indeed rich in collagen (which, when produced by the human body, strengthens hair and skin). Whey powder, made from leftover cheese water, does contain protein. But very few studies support the idea that eating more collagen strengthens hair and skin. Whey protein can help build lean muscle, but the body can only absorb so much at a time. Some dermatologists say tallow can strengthen and hydrate the skin; others say it clogs pores and should be avoided. Other products can be downright dangerous: Just this week, Florida officials announced that 21 people fell sick after consuming contaminated raw milk.
At least part of the appeal of cowmaxxing is the cows themselves: The products evoke the pastoral ideal of a cow grazing freely in the plains, milked lovingly by human hands. It's an image that's been embedded in American culture for centuries. Consider how Laura Ingalls Wilder, who was no stranger to the harsh reality of farm life, described cow-raising in Little Town on the Prairie: 'Warm and sweet, the scent of new milk came up from the streams hissing into the rising foam, and it mixed with the scents of springtime.' It's enough to persuade a microbiologist to drink raw milk.
In 21st-century America, cows still summon images of fields and clover and wide blue sky, enough to trigger the human tendency to believe that what's natural is 'fundamentally good,' Courtney Lappas, a biology professor at Lebanon Valley College, told me. Her research has shown that some Americans prefer natural over man-made products even when the former is described as objectively worse—a phenomenon her colleague Brian Meier has called the 'naturalness bias.' This tendency, which is prevalent across cultures, likely leads people to assume that unprocessed cow-based products are safe and healthy, she said. Tallow, some skin-care enthusiasts claim, is a healthier, safer alternative to conventional moisturizers, which supposedly contain toxic chemicals. The branding of such products, too, leans into the notion that natural is best: Fat Cow Skincare markets its tallow cosmetics as 'pure skincare, powered by nature'; Heart and Soil sells capsules of 'nature's superfood' (that is, organ meats). Other brands invoke nature through the prehistoric, with names such as Primal Harvest, Primal Kitchen, Primal FX, Primal Being, and Primal Queen. Ancestral Supplements' ad copy reads: 'Putting Back In What the Modern World Left Out.'
America's current health landscape is the perfect setting for cowmaxxing to thrive. The naturalness bias is deeply ingrained in Kennedy's MAHA campaign, which aims to improve public health by returning to a more natural lifestyle. In Kennedy's view, beef tallow is superior to seed oil because it's less processed (some people even render it at home). The carnivore and tradwife movements embody a similar message, promoting the consumption of raw cow organs and making butter from scratch. You may not know what's in store-bought products, the thinking goes, but you do know what's in tallow: pure, unadulterated cow fat.
And yet most modern cows live in a decidedly unnatural environment. The majority of U.S. cattle are fed genetically modified crops, and some genetically modified cows are allowed to be sold as food. Many cow-based wellness products bear the label 'grass-fed,' which suggests cows that were raised on pastures rather than feedlots. But the label is not strictly enforced, and it doesn't necessarily prohibit farmers from giving cows antibiotics or hormones. There's no guarantee that a cow whose colostrum is harvested to be sold by a tradwife on Instagram had a happy, bucolic existence. Not to mention that colostrum, whey, and placenta do not come out of the cow in the form of powders or pills.
The spread of science misinformation, along with legitimate concerns about the state of public health in the United States, have left many Americans understandably confused about whether conventional science and Western medicine can be trusted in 2025. Getting to the bottom of, say, the seed-oil controversy requires engaging with thorny scientific debates that reference inscrutable research papers; embracing the natural and ancestral by opting for tallow is an attractively simple-seeming alternative. 'It brings with it a sense of purity or wholesomeness that is desirable right now,' Marianne Clark, a sociologist at Acadia University who studies wellness trends, told me. In this sense, cowmaxxing is not so much a health endeavor as it is a spiritual one, its promise downright biblical: Cowliness is next to godliness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
Why young Americans dread turning 26 as they face health insurance chaos
Amid the challenges of adulthood, one rite of passage is unique to the United States: the need to find your own health insurance by the time you turn 26. That is the age at which the Affordable Care Act declares that young adults generally must get off their family's plan and figure out their coverage themselves. When the ACA was voted into law in 2010, what's known as its dependent coverage expansion was immediately effective, guaranteeing health insurance to millions of young Americans up to age 26 who would otherwise not have had coverage. But for years, Republicans have whittled away at the infrastructure of the original ACA. Long gone is the requirement to buy insurance. Plans sold in the ACA's online insurance marketplaces have no stringent quality standards. Costs keep rising, and eligibility requirements and subsidies are moving targets. The erosion of the law has now created an 'insurance cliff' for Americans who are turning 26 and don't have a job that provides medical coverage. Some, scared off by the complexity of picking a policy and by the price tags, tumble over the edge and go without insurance in a health system where the rate for an emergency room visit can be thousands, if not tens of thousands, of dollars. Today, an estimated 15% of 26-year-olds go uninsured, which, according to a KFF analysis, is the highest rate among Americans of any age. If they qualify, young adults can sign up for Medicaid, the federal-state program for Americans with low incomes or disabilities, in most but not all states. Otherwise, many buy cheap subpar insurance that leaves them with insurmountable debt following a medical crisis. Others choose plans with extremely limited networks, losing access to longtime doctors and medicines. They often find those policies online, in what has become a dizzyingly complicated system of government-regulated insurance marketplaces created by the ACA. The marketplaces vary in quality from state to state; some are far better than others. But they generally offer few easily identifiable, affordable, and workable choices. 'The good news is that the ACA gave young people more options,' said Karen Pollitz, who directed consumer information and insurance oversight at the Department of Health and Human Services during the Obama administration. 'The bad news is the good stuff is hidden in a minefield of really bad options that'll leave you broke if you get sick.' Publicly funded counselors called 'navigators' or 'assisters' can help insurance seekers choose a plan. But those programs vary by state, and often customers don't realize that the help is available. The Trump administration has cut funding to publicize and operate those navigator programs. In addition, changes to Medicaid eligibility in the policy bill recently passed by Congress could mean that millions more ACA enrollees lose their insurance, according to the Congressional Budget Office. Those changes threaten the very viability of the ACA marketplaces, which currently provide insurance to 24 million Americans. In dozens of interviews, young adults described the unsettling and devastating consequences of having inadequate insurance, or no insurance at all. Damian Phillips, 26, a reporter at a West Virginia newspaper, considered joining the Navy to get insurance as his 26th birthday approached. Instead, he felt he 'didn't make enough to justify having health insurance' and has reluctantly gone without it. Ethan Evans, a 27-year-old aspiring actor in Chicago who works in retail, fell off his parents' plan and temporarily signed up for Medicaid. But the diminished mental health coverage meant cutting back on visits to his longtime therapist. Rep. Maxwell Frost, a Florida Democrat and the first Gen Z member of Congress, was able to quit his job and run for office at 25 only because he could stay on his mother's plan until he turned 26, he said. Now 28, he is insured through his federal job. 'The ACA was groundbreaking legislation, including the idea that every American needs health care,' he said. 'But there are pitfalls, and one of them is that when young adults turn 26, they fall into this abyss.' Back in 2010, the decision to make 26 the cutoff age for staying on a parent's insurance was 'kind of arbitrary,' recalled Nancy-Ann DeParle, deputy chief of staff for policy in the Obama White House. 'My kids were young , and I was trying to imagine when my child would be an adult.' Before that time, children were often kicked off family plans at much younger ages, typically 18. The Obama administration's idea was that young adults were most likely settling into careers and jobs with insurance by 26. If they still didn't have access to job-based insurance, Medicaid and the ACA marketplaces would offer alternatives, the thinking went. But over the years, the courts, Congress, and the first Trump administration eviscerated provisions of the ACA. By 2022, a shopper on a federal government-run marketplace had more than 100 choices, many of which included expensive trade-offs, presented in a way that made comparisons difficult without spreadsheets. Jack Galanty, 26, a freelance designer in Los Angeles, tried to plan for his 26th birthday by seeking coverage on the California insurance marketplace that would ensure treatment for his mild cerebral palsy and for HIV prevention. 'You're scrolling for what feels like years, looking at 450 little slides, at the little bars, and trying to remember, 'Was the one I liked No. 12 or 13?'' he recalled. 'It feels like it's nearly impossible to make a good choice in this scenario.' Out-of-pocket expenses have soared. Complex plans in the lightly regulated marketplaces featured rising premiums, high deductibles, and requirements that patients pay a significant portion of the cost of care, often 20% — a charge known as coinsurance. More than half of Americans ages 18 to 29 have incurred medical debt in the past five years, a KFF Health News data investigation found. Few have the reserves to pay it off. The networks of doctors to choose from in these plans are often so limited that an insured person struggles to get timely appointments. It can even be hard to find the official websites amid an explosion of look-alikes operated by commercial brokers. Sharing her contact information with one site that appeared legitimate left Lydia Herne, a social media producer in Brooklyn, 'drowning' in texts and phone calls offering plans of uncertain and unregulated quality. 'It never ends,' said Herne, 27. Young Invincibles, an advocacy group representing young adults, runs its own 'navigator' program to help young people choose health insurance plans. 'We hear the frustration,' said Martha Sanchez, the group's former director of health policy and advocacy. 'Twenty-six-year-olds have had negative experiences in a process that's become really complex. Many throw up their hands.' Elizabeth Mathis, 29, and Evan Pack, 30, a married couple in Salt Lake City, turned to the marketplaces two years ago, after Pack went uninsured for a 'really scary' year after he turned 26. 'Every time he got in the car, I thought, 'What if?'' Mathis said. The couple pays more than $200 a month for a high-deductible health plan backed by a federal subsidy (the kind set to expire next year). It's a significant expense, but they wanted to be sure they had access to contraception and an antidepressant. But last year, Pack suffered serious eye problems and underwent an emergency appendectomy. Their plan left them $9,000 in debt, for medical care billed at over $20,000. 'Technically, we gambled in the right direction,' Mathis said. 'But I don't feel like we've won.' The ACA was supposed to help consumers find affordable, high-quality plans online. The legislation also tried to expand Medicaid programs, which are administered by states, to provide health insurance to low-income Americans. But the Supreme Court ruled in 2012 that states could not be forced to expand Medicaid. Ten states, led mostly by Republicans, have not done so, leaving up to 1.5 million Americans, who could have qualified for coverage, without insurance. Even where Medicaid is available to 26-year-olds, the transition has often proved precarious. Madeline Nelkin of New Jersey, who was studying social work, applied for Medicaid coverage before her 26th birthday in April 2024 because her university's insurance premiums were more than $5,000 annually. But it was September before her Medicaid coverage kicked in, leaving her uninsured while she fought a chest infection over the summer. 'People tell you to think ahead, but I didn't think that meant six months,' she said. When Megan Hughes, 27, of Hartland, Maine, hit the cliff, she went without. An aide for children with developmental delays, she has a thyroid condition and polycystic ovary syndrome. She looked for a health care plan but found it hard to understand the marketplace. (She didn't know there were navigators who could help.) Now she can't afford her medicine or see her endocrinologist. 'I'm tired all the time,' Hughes said. 'My cycles are not regular anymore at all. When I do get one, it's debilitating.' She is hoping a new job will provide insurance later this year. Traditionally, most Americans with private health insurance got it through their jobs. But the job market has changed dramatically since the ACA became law, particularly in the wake of the pandemic, with the rise of a gig economy. Over 30% of people ages 18 to 29 said in recent surveys that they were working or have worked in short-term, part-time, or irregular jobs. The ACA requires organizations with 50 or more employees to offer insurance to people working 30 hours per week. This has led to a growing number of contract employees who work up to, but not past, the hourly limit. Many companies, which say they can't afford the rising costs of traditional insurance, offer their employees only a modicum of help, perhaps around $200 per month toward buying a marketplace plan, or a bare-bones company plan. Young people juggling part-time jobs and insurance options face bumpy, daunting transitions. In Oklahoma, Daisy Creager, 29, has had three employers over the past three years. Insurance was important to her, not least because her former husband had Type 1 diabetes. As she left the first of those jobs, her husband's endocrinologist helped the couple stockpile less expensive insulin from Canada, since they would be uninsured. After a few months, they bought a marketplace plan, but it was expensive and 'didn't cover a lot,' she said. When she found a new job, she dropped that plan, only to discover that her new insurance coverage didn't start until the end of her first month of employment. The couple would be uninsured for a few weeks. A few days later, she came home to find her husband unconscious on the floor, in a diabetic coma. After hovering near death in an intensive care unit for four days, he woke up and began to recover. 'I think I've done everything right,' Creager said. 'So why am I in a position where the health insurance available to me doesn't cover what I need, or I can barely afford my premiums, or worse, at times I don't even have it?' Kathryn Russell, 27, developed excruciating back pain two months before her 26th birthday. After extensive testing, doctors determined she needed a complex surgery, which her surgeon couldn't schedule until after she would be off her family's insurance plan. Forget the pain and the fear of the operation, she said, it was insurance that kept her up at night. 'There's this impending terror of, 'What am I going to do?'' she recalled. (One day before she turned 26, her father's company agreed to keep her on his plan for six more months, if he paid higher premiums.) The idea that the ACA would offer a variety of good options for people turning 26 has not worked as well as the legislation's authors had hoped. The 'job lock' tying insurance to employment has long plagued the United States workforce. Young adults need guidance on their options beforehand, said Sanchez of Young Invincibles. None of those interviewed for this story, for example, knew there were navigators to help them find insurance on the online marketplaces. Experts agree that the marketplaces need stronger regulation. In 2023, the federal government defined clearer standards for what plans in each tier of insurance should offer, such as better prescription drug benefits, defined copays for X-rays, or coverage for emergency room visits. Certain types of basic care, such as primary care, should require just a small copay for at least a small number of initial visits. Each insurer must offer at least one plan that complies with these new standards for every level, known as an 'easy pricing' option or a 'standard plan.' Most plans on the marketplaces don't meet these criteria. Federal and state regulators had long planned to cull such 'noncompliant' plans, gradually — fearing that doing so too quickly would scare insurers away from participating. But with the priorities of the new Trump administration now in focus, and a Republican majority in Congress, it's far from clear what course President Donald Trump, who sought to repeal the ACA outright in his first term, will take. There are hints: Subsidies to help Americans buy insurance, adopted during the Biden administration, are set to expire at the end of 2025 unless the Republican-led Congress extends them. If the subsidies expire, premiums are likely to rise sharply for plans sold on the marketplaces, leaving insurance out of reach for many more young adults. KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism.
Politico
2 hours ago
- Politico
More questions about Prasad's return
Driving the Day BACK TO CBER — Dr. Vinay Prasad has returned to the FDA's Center for Biologics Evaluation and Research, leaving industry and public health observers puzzled over what happened during his brief absence to account for his reinstatement. The hematologist-oncologist's time away from the agency — equivalent to one Scaramucci (IYKYK) — came after President Donald Trump overruled FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr. and called for his firing amid conservative backlash to Prasad's past political statements and recent decisions around rare disease drugs. Makary told reporters last week he was trying to bring Prasad back to the FDA. But as of Monday afternoon, the FDA website continued to list the Center for Drug Evaluation and Research's director, George Tidmarsh, as CBER's acting leader. Several key questions remain as Prasad, long known as a firebrand in his own right, returns to White Oak. Here are some outstanding questions we have: How will he approach regulatory decisions for rare disease therapies? It's unclear whether the White House has weighed in on Prasad's earlier actions that sparked worry among patient advocates and industry that he would take a harder line on rare disease drug approvals than his predecessors. Those therapies face more obstacles to market because the pool of people who can vet them via controlled trials is inherently tiny, meaning companies often rely on surrogate endpoints — outcomes that can predict clinical significance — to convey their benefit. Prasad had previously criticized the agency for approving Sarepta's Elevidys for Duchenne muscular dystrophy, arguing it posed questionable benefits given its potential risks and high price tag. Stocks in Sarepta and other CBER-regulated companies fell Monday morning as the markets opened for the first time since Prasad's return was reported. Financial analysts in client notes sent Monday were divided on how bullish industry should be in interpreting his second tour as friendlier than his first. How many hats will he wear? During his first FDA stint, Prasad racked up titles to include chief medical and scientific officer, signifying Makary's faith in him as his right hand. Whether he'll reclaim them remains unclear. What's next for CBER on vaccines? Prasad has already effected one of the biggest changes he sought in U.S. Covid vaccine policy by reorienting FDA approval of future formulations toward high-risk populations, absent new randomized trials showing benefit to young, otherwise healthy individuals. But everyone closely watching Kennedy suspects more changes are coming to the federal government's stewardship of vaccines, and CBER is the checkpoint for which shots reach the market. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. What should we do this week now that the MAHA report isn't hitting our desks? Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). AROUND THE AGENCIES CDC SHOOTING FALLOUT — HHS Secretary Robert F. Kennedy Jr. visited the agency's Atlanta headquarters Monday to survey the damage from Friday's fatal shooting with newly confirmed CDC Director Susan Monarez. Meanwhile, CDC employees are afraid to return to work after the shooting, three agency staffers told POLITICO's Sophie Gardner. No agency workers were hurt, but a local police officer was shot and killed while responding. 'Even the ones who weren't in lockdown for seven hours and are ridiculously traumatized … [are asking] 'Are our windows bulletproof? And what about the areas without cell reception?'' another staffer said. They were granted anonymity for fear of retribution. Some media outlets have reported that the suspected shooter, 30-year-old Patrick White, believed that the Covid-19 vaccine made him sick. White died at the scene, authorities said. 'I think most of us would very much like the next message we hear from him to begin with 'I hereby resign,'' another employee told POLITICO in a text. 'The secretary is being widely (and accurately) blamed for spreading disinformation about vaccines that helped poison the mind of a disturbed individual.' HHS spokesperson Andrew Nixon said in a statement that Kennedy 'unequivocally condemned the horrific attack and remains fully committed to ensuring the safety and well-being of CDC employees.' What's next: The CDC has extended telework for a week to everyone who works from agency campuses in Atlanta. It's unclear when employees will be expected to return to the agency's Edward R. Roybal campus, which sustained extensive damage. Industry Intel NEW CANCER VAX DATA — IO Biotech's cancer vaccine Cylembio helped slow the progression of disease in advanced melanoma patients who took it in combination with Merck's Keytruda, the company said Monday, but it narrowly missed its window for statistical significance. The investigational shot is designed as an off-the-shelf option targeting both tumor and immune-suppressive cells. IO Biotech said it plans to meet with the FDA this fall to discuss the data and identify a path forward to apply for regulatory approval. The mRNA elephant: Those results came days after HHS Secretary Robert F. Kennedy Jr.'s announcement curtailing federal support for certain messenger RNA vaccine projects — a move that spurred concern among cancer-focused pharma companies and patient advocates, Lauren writes. That's because mRNA technology could transform cancer treatment thanks to its rapid manufacturing process and ability to be customized to instruct a recipient's immune system to attack their unique tumor. Dozens of treatments are being studied or advanced in company pipelines. While Kennedy's decision last week focused on vaccines for respiratory viruses, mRNA boosters say his disdain for the technology raises questions about the FDA's posture toward those therapies for other disease areas — and poses risks that some firms may ultimately decide to avoid by moving operations abroad. They also worry about the lasting impacts of his rhetoric on public acceptance of mRNA-based products, even if they're eventually available for stubborn cancers with few treatment options. HHS response: A spokesperson called the industry's assessment of potential fallout 'false.' Eye on the FDA CAPRICOR HEADS TO FDA — Executives from Capricor Therapeutics will meet with FDA officials this week to discuss the agency's rejection last month of its application for a cell therapy to treat heart issues in people with Duchenne muscular dystrophy, CEO Linda Marbán said Monday during the company's second-quarter earnings call. Capricor wants to resubmit its application — which the company has maintained closely followed earlier agency feedback on its data — based on its existing dataset, Marbán said. The firm may also include information from an ongoing trial, depending on the FDA's responses this week. When asked how Dr. Vinay Prasad's return to the agency affects the company's thinking, Marbán said she's taking an 'old-school' approach. 'We have good clinical data, we have great safety data, we have guidance from the agency in writing as to what they wanted. We provided it,' she said. 'And now, really, I think it's up to them to decide who is best suited within that agency to make the decision of adjudication and all of the factors that go into it.' FDA RELEASES DRUG-QUALITY REPORT — A few interesting nuggets are buried in an annual FDA report on the quality of pharmaceuticals in the U.S. The Center for Drug Evaluation and Research's catalog lists 4,619 global manufacturing sites that make drugs for American patients as of the end of September 2024 — with 41 percent located within the U.S. In fiscal 2024, the agency noted that 62 percent of drug-quality assurance inspections were conducted at foreign sites, the highest mark to date. Increasing the number of foreign inspections has been a top priority of FDA Commissioner Marty Makary. 'This progress in foreign inspections was particularly evident in India and China, where 34% and 28% of sites in the Site Catalog, respectively, were inspected,' the report states. 'By comparison, 24% of the U.S. sites in the Site Catalog were inspected in FY2024.' Pharma Moves Jennifer Tomasello is joining AdvaMed as a senior director of federal government affairs. She previously worked at the FDA as a senior policy adviser in the Center for Devices and Radiological Health. WHAT WE'RE READING The U.S. Postal Service is blocking some shipments of vapes that lack marketing authorization from the FDA, Reuters' Emma Rumney reports. The Guardian's Melody Schreiber reports that Pfizer's Covid-19 vaccine for young children under 5 years old might not have its emergency use authorization renewed for the 2025 fall respiratory season.
Bloomberg
2 hours ago
- Bloomberg
Insmed Drug Wins First US Approval for Debilitating Lung Disease
US regulators have approved the first drug to treat a debilitating lung condition, ending two centuries of waiting and paving the way for a potential blockbuster from Insmed Inc. The once-daily pill, called Brinsupri and known chemically as brensocatib, eases bronchiectasis, a chronic inflammatory disease that damages the airways and can make it hard to breathe. Patients struggle to clear mucus from their lungs, which creates a breeding ground for infections and often lands them in the hospital for long periods.
